CORRELATION OF VASCULAR ENDOTHELIAL FUNCTION AND INFLAMMATORY FACTORS WITH RENAL FUNCTION IN PATIENTS WITH DIABETIC NEPHROPATHY

Authors:

Abstract:

The purpose of the study was to examine the interrelation between vascular endothelial function and inflammatory factors with renal function in patients diagnosed with diabetic nephropathy. A total of 120 patients with diabetic nephropathy were enrolled in this study. The patients were categorized based on the stage of diabetic nephropathy: Group I – normoalbuminuria (n=30), Group II – microalbuminuria (n=30), Group III – macroalbuminuria (n=30), Group IV – patients with clinical nephropathy (n=30). The levels of creatinine, endothelin-1, nitric oxide, interleukin-6, interleukin-10, tumor necrosis factor-alpha in the blood and glomerular filtration rate were determined. There was a correlation between glomerular filtration rate and blood endothelin-1 (r=0.517 (p<0.01) in Group I, r=-0.74 (p<0.01) in Group III, r=-0.566 (p<0.01) in Group IV); and with tumor necrosis factor-alpha: in Group 1 (r=0.589 (p<0.01), in Group II (r=0.5451 (p<0.05), in Group III (r=-0.531 (p<0.01) and in Group IV (r=-0.64 (p<0.01). Our findings suggest significant associations between endothelial biomarkers, inflammatory factors, and renal function at various stages of diabetic nephropathy.

Keywords:

diabetic nephropathy glomerular filtration rate interleukin endothelin-1 tumor necrosis factor-alpha

References:

1. Agayev M, Mammadova I, Ismayilova Sh, SP315. Influence of lipid metabolism disorders on endothelial function in chronic kidney disease, Nephrology Dialysis Transplantation, Volume 30, Issue suppl_3, May 2015, Page iii483, https://doi.org/10.1093/ndt/gfv191.35
2. Ahn JH, Yu JH, Ko SH, Kwon HS, Kim DJ, Kim JH, et al; Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination survey. Diabetes Metab J. 2014 Apr;38(2):109–19. doi: 10.4093/dmj.2014.38.2.109.
3. Chavarria-Buenrostro LE, Hernandez-Bello J, Muñoz-Valle JF, Macias-Barragan J, Hernandez-Carrillo LB, Topete-Reyes JF, et al. IL-10 haplotypes are associated with diabetic nephropathy susceptibility in patients from western Mexico. J Clin Lab Anal. 2019 Feb;33(2):e22691. doi: 10.1002/jcla.22691.
4. Cheng HT, Xu X, Lim PS, Hung KY. Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015. Diabetes Care. 2021 Jan;44(1):89-97. doi: 10.2337/dc20-1913.
5. El-Edel RH, Fathy WM, Abou-Elela DH, Emara MM, Abo El-Khair NT. Role of tumor necrosis factor alpha in type 2 diabetic nephropathy. Menoufia Med J 2020; 33:920–5. http://www.mmj.eg.net/text.asp?2020/33/3/920/296693
6. Finne P, Groop PH, Arffman M, Kervinen M, Helve J, Grönhagen-Riska C, et al. Cumulative Risk of End-Stage Renal Disease Among Patients With Type 2 Diabetes: A Nationwide Inception Cohort Study. Diabetes Care. 2019 Apr;42(4):539–544. doi: 10.2337/dc18-1485.
7. Katerenchuk IP, Rustamian ST. Assessment of adhesion to treatment of patients being on kidney replacement therapy taking into account the presence of type 2 diabetes mellitus. World of medicine and biology. 2021; 3 (77):73–77. DOI 10.26724/2079-8334-2021-3-77-73-77
8. Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: definition and classification of CKD. Kidney Int Suppl 2013; 3:19–62.
9. Mamedzade AY, Ismailova SH, Mamedova V, Alekperova A, Mamedli S, Musayeva T. Otsenka sosudistoy endotelialnoy funktsii neinvazivnim metodom na razlichnykh stadiyakh khronicheskoy bolezni pochek. Azerbaydzhanskiy Meditsinskiy Zhurnal, 2022; 1: 71–74. https://doi.org/10.34921/amj.2022.1.011. [In Russian]
10. Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013; 2013:248563. doi:10.1155/2013/248563
11. Mizdrak M, Kumrić M, Kurir TT, Božić J. Emerging Biomarkers for Early Detection of Chronic Kidney Disease. J Pers Med. 2022 Mar 31;12(4):548. doi: 10.3390/jpm12040548.
12. Reutens AT. Epidemiology of diabetic kidney disease. The Medical clinics of North America, 2013, 97(1), 1–18. https://doi.org/10.1016/j.mcna.2012.10.001
13. Sanchez-Alamo B, Shabaka A, Cachofeiro V, Cases-Corona C, Fernandez-Juarez G; PRONEDI study investigators. Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy. Clin Nephrol. 2022 Jan;97(1):1–9. doi: 10.5414/CN110223. PMID: 34753557.
14. Sato Y, Yanagita M. Immune cells and inflammation in AKI to CKD progression. Am J Physiol Renal Physiol. 2018 Dec 1; 315(6): F1501-F1512. doi: 10.1152/ajprenal.00195.2018.
15. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–152. doi:10.1042/CS20120198

Publication:

«World of Medicine and Biology» Vol. 19 No. 85 (2023) , с. 129-132
УДК 616.379-008: 616.4-092

DOI:

https://doi.org/10.26724/2079-8334-2023-3-85-129-132